EMBC vs. NARI, ICUI, IART, NVCR, UFPT, LMAT, ATEC, ATRC, MDXG, and AORT
Should you be buying Embecta stock or one of its competitors? The main competitors of Embecta include Inari Medical (NARI), ICU Medical (ICUI), Integra LifeSciences (IART), NovoCure (NVCR), UFP Technologies (UFPT), LeMaitre Vascular (LMAT), Alphatec (ATEC), AtriCure (ATRC), MiMedx Group (MDXG), and Artivion (AORT). These companies are all part of the "surgical & medical instruments" industry.
Embecta (NASDAQ:EMBC) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends, earnings and community ranking.
93.8% of Embecta shares are held by institutional investors. Comparatively, 91.0% of Inari Medical shares are held by institutional investors. 0.3% of Embecta shares are held by company insiders. Comparatively, 10.6% of Inari Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Inari Medical received 58 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 68.24% of users gave Inari Medical an outperform vote while only 0.00% of users gave Embecta an outperform vote.
In the previous week, Inari Medical had 25 more articles in the media than Embecta. MarketBeat recorded 27 mentions for Inari Medical and 2 mentions for Embecta. Embecta's average media sentiment score of 1.80 beat Inari Medical's score of 0.06 indicating that Embecta is being referred to more favorably in the media.
Embecta presently has a consensus target price of $13.00, suggesting a potential upside of 7.79%. Inari Medical has a consensus target price of $65.71, suggesting a potential upside of 41.56%. Given Inari Medical's stronger consensus rating and higher possible upside, analysts plainly believe Inari Medical is more favorable than Embecta.
Embecta has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Inari Medical has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Embecta has a net margin of 6.20% compared to Inari Medical's net margin of -4.54%. Inari Medical's return on equity of -1.65% beat Embecta's return on equity.
Embecta has higher revenue and earnings than Inari Medical. Inari Medical is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
Summary
Inari Medical beats Embecta on 10 of the 18 factors compared between the two stocks.
Get Embecta News Delivered to You Automatically
Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
